- Home
- HUBB vs MRNA Comparison
HUBB vs MRNA Comparison
Compare HUBB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUBB | MRNA |
|---|---|---|
| Founded | 1888 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 19.7B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HUBB | MRNA |
|---|---|---|
| Price | $537.25 | $50.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | ★ $517.88 | $34.27 |
| AVG Volume (30 Days) | 505.2K | ★ 5.3M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | 15.10 | ★ 21.77 |
| EPS | ★ 16.54 | N/A |
| Revenue | $5,844,600,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $10.34 | $8.74 |
| Revenue Next Year | $5.47 | $16.18 |
| P/E Ratio | $32.30 | ★ N/A |
| Revenue Growth | 3.84 | ★ 4.29 |
| 52 Week Low | $325.08 | $22.28 |
| 52 Week High | $536.97 | $59.55 |
Technical Indicators
Market Signals| Indicator | HUBB | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.22 | 50.91 |
| Support Level | $416.52 | $47.61 |
| Resistance Level | N/A | $54.94 |
| Average True Range (ATR) | 15.05 | 2.53 |
| MACD | 6.10 | -0.21 |
| Stochastic Oscillator | 91.47 | 50.66 |
Price Performance
Historical ComparisonAbout HUBB Hubbell Inc
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, in electrical substations, and in commercial and industrial buildings. The company's primary operations are in the United States, where around 90% of revenue is derived.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.